Beacon Therapeutics enters gene therapy arena with $120m launch

Beacon Therapeutics has kickstarted its entry into the gene therapy field with a $120m Series A financing.

The British investment trust Syncona Limited launched the new ophthalmic gene therapy company by combining Applied Genetic Technologies Corporation’s (AGTC’s) late-stage X-linked retinitis pigmentosa (XLRP) programme with two proprietary preclinical programmes.

The funding, with participation from Oxford Science Enterprises (OSE), includes AGTC’s acquisition and capital to help accelerate Beacon Therapeutics’ candidate development. The total financing was £96m ($120m).

In late 2022, Syncona acquired AGTC for $23.5m and with it a portfolio of ophthalmic pipeline candidates. Amongst it was AGTC’s lead clinical candidate, AFTC-501, an adeno-associated virus (AAV) gene therapy for XLRP. The asset, now transferred to Beacon Therapeutics, is currently in Phase II clinical trials.

According to Beacon Therapeutics, AGTC-501 is unique from other treatment approaches since it addresses the entirety of photoreceptor damage – both rod and cone loss – caused by XLRP. Beacon Therapeutics says it expects 12-month data from the SKYLINE trial in H2 2023.

Beacon Therapeutics also has two preclinical assets in its portfolio: an intravitreally (IVT) delivered AAV based program for dry age-related macular degeneration (dry AMD) and a programme licensed from the University of Oxford that targets cone-rod dystrophy.

Beacon Therapeutics is the third gene therapy company Syncona has launched. Two previous portfolio investments, Nightstar and Gyroscope, were sold for $877m to Biogen and $1.5bn to Novartis respectively.

“With the 12-month data from our Phase II SKYLINE trial for AGTC-501 expected shortly and two highly innovative and differentiated pipeline assets for prevalent and rare blinding diseases, we are excited to be building a new leader in the ophthalmic gene therapy space,” said David Fellows, Beacon Therapeutics’ CEO in a statement announcing the company launch.

GlobalData is the parent company of Pharmaceutical Technology.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.

By Cytiva Thematic

By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy